JP2010115195A5 - - Google Patents

Download PDF

Info

Publication number
JP2010115195A5
JP2010115195A5 JP2009253394A JP2009253394A JP2010115195A5 JP 2010115195 A5 JP2010115195 A5 JP 2010115195A5 JP 2009253394 A JP2009253394 A JP 2009253394A JP 2009253394 A JP2009253394 A JP 2009253394A JP 2010115195 A5 JP2010115195 A5 JP 2010115195A5
Authority
JP
Japan
Prior art keywords
mammal
test sample
immune response
detecting
tissue cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009253394A
Other languages
English (en)
Other versions
JP2010115195A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010115195A publication Critical patent/JP2010115195A/ja
Publication of JP2010115195A5 publication Critical patent/JP2010115195A5/ja
Pending legal-status Critical Current

Links

Claims (14)

  1. 哺乳動物の免疫関連疾患の検出方法であって、(a)哺乳動物から採取した組織細胞の試験試料中、及び(b)同じ細胞型の既知の正常組織細胞のコントロール試料中における、配列番号1136に示すアミノ酸配列を有するポリペプチドをコードする遺伝子の発現レベルを検出することを含み、このときコントロール試料と比較して試験試料中における該遺伝子の発現レベルが高いか又は低いことにより、試験組織細胞が採取された哺乳動物における免疫関連疾患の存在が示される方法。
  2. 哺乳動物の免疫関連疾患の検出方法であって、(a)哺乳動物から採取した組織細胞の試験試料と、配列番号1136に示すアミノ酸配列に結合する抗体とを接触させることと、(b)抗体と試験試料中のポリペプチドとの間の複合体の形成を検出することを含み、このとき該複合体の形成により、試験組織細胞が採取された哺乳動物における免疫関連疾患の存在が示される方法。
  3. 免疫関連疾患がT細胞媒介性免疫疾患である、請求項1又は2に記載の方法。
  4. 哺乳動物の炎症性免疫反応の検出方法であって、(a)哺乳動物から採取した組織細胞の試験試料中、及び(b)同じ細胞型の既知の正常組織細胞のコントロール試料中における、配列番号1136に示すアミノ酸配列を有するポリペプチドをコードする遺伝子の発現レベルを検出することを含み、このときコントロール試料と比較して試験試料中における該遺伝子の発現レベルが高いか又は低いことにより、試験組織細胞が採取された哺乳動物における炎症性免疫反応の存在が示される方法。
  5. 哺乳動物の炎症性免疫反応の検出方法であって、(a)哺乳動物から採取した組織細胞の試験試料と、配列番号1136に示すアミノ酸配列に結合する抗体とを接触させることと、(b)抗体と試験試料中のポリペプチドとの間の複合体の形成を検出することを含み、このとき該複合体の形成により、試験組織細胞が採取された哺乳動物における炎症性免疫反応の存在が示される方法。
  6. 炎症性免疫反応がT細胞媒介性免疫反応である、請求項4又は5に記載の方法。
  7. T細胞媒介性免疫反応がCD45RO T細胞媒介性反応である、請求項6に記載の方法。
  8. 哺乳動物の免疫関連疾患を診断するためのキットであって、(a)哺乳動物から採取した組織細胞の試験試料中、及び(b)同じ細胞型の既知の正常組織細胞のコントロール試料中における、配列番号1136に示すアミノ酸配列を有するポリペプチドをコードする遺伝子の発現レベルを検出するための手段を具備し、このときコントロール試料と比較して試験試料中における該遺伝子の発現レベルが高いか又は低いことにより、試験組織細胞が採取された哺乳動物における免疫関連疾患の存在が示されるキット。
  9. 哺乳動物の免疫関連疾患を診断するためのキットであって、(a)哺乳動物から採取した組織細胞の試験試料と、配列番号1136に示すアミノ酸配列を有するポリペプチドに結合する抗体とを接触させるための手段と、(b)抗体と試験試料中のポリペプチドとの間の複合体の形成を検出するための手段とを具備し、このとき該複合体の形成により、試験組織細胞が採取された哺乳動物における免疫関連疾患の存在が示されるキット。
  10. 免疫関連疾患がT細胞媒介性免疫疾患である、請求項8又は9に記載のキット。
  11. 哺乳動物の炎症性免疫反応を診断するためのキットであって、(a)哺乳動物から採取した組織細胞の試験試料中、及び(b)同じ細胞型の既知の正常組織細胞のコントロール試料中における、配列番号1136に示すアミノ酸配列を有するポリペプチドをコードする遺伝子の発現レベルを検出するための手段を具備し、このときコントロール試料と比較して試験試料中における該遺伝子の発現レベルが高いか又は低いことにより、試験組織細胞が採取された哺乳動物における炎症性免疫反応の存在が示されるキット。
  12. 哺乳動物の炎症性免疫反応を診断するためのキットであって、(a)哺乳動物から採取した組織細胞の試験試料と、配列番号1136に示すアミノ酸配列を有するポリペプチドに結合する抗体とを接触させるための手段と、(b)抗体と試験試料中のポリペプチドとの間の複合体の形成を検出するための手段とを具備し、このとき該複合体の形成により、試験組織細胞が採取された哺乳動物における炎症性免疫反応の存在が示されるキット。
  13. 炎症性免疫反応がT細胞媒介性免疫反応である、請求項11又は12に記載のキット。
  14. T細胞媒介性免疫反応がCD45RO T細胞媒介性反応である、請求項13に記載のキット。
JP2009253394A 2002-10-29 2009-11-04 免疫関連疾患の治療のための新規組成物と方法 Pending JP2010115195A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42247202P 2002-10-29 2002-10-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004548574A Division JP2006517785A (ja) 2002-10-29 2003-10-28 免疫関連疾患の治療のための新規組成物と方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012187148A Division JP2012254093A (ja) 2002-10-29 2012-08-28 免疫関連疾患の治療のための新規組成物と方法

Publications (2)

Publication Number Publication Date
JP2010115195A JP2010115195A (ja) 2010-05-27
JP2010115195A5 true JP2010115195A5 (ja) 2011-04-14

Family

ID=32230357

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004548574A Pending JP2006517785A (ja) 2002-10-29 2003-10-28 免疫関連疾患の治療のための新規組成物と方法
JP2009253394A Pending JP2010115195A (ja) 2002-10-29 2009-11-04 免疫関連疾患の治療のための新規組成物と方法
JP2012187148A Pending JP2012254093A (ja) 2002-10-29 2012-08-28 免疫関連疾患の治療のための新規組成物と方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004548574A Pending JP2006517785A (ja) 2002-10-29 2003-10-28 免疫関連疾患の治療のための新規組成物と方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012187148A Pending JP2012254093A (ja) 2002-10-29 2012-08-28 免疫関連疾患の治療のための新規組成物と方法

Country Status (6)

Country Link
US (2) US20070185017A1 (ja)
EP (5) EP2322200A3 (ja)
JP (3) JP2006517785A (ja)
AU (2) AU2003298607B9 (ja)
CA (1) CA2503330A1 (ja)
WO (1) WO2004039956A2 (ja)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479555B2 (en) 1999-07-21 2009-01-20 Ceres, Inc. Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DE602004019556D1 (de) * 2003-10-30 2009-04-02 Kazusa Dna Res Instutite Found Neues plexin-polypeptid, dieses codierende dna und verwendung davon
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005106488A2 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2)
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
JP2006042802A (ja) * 2004-06-28 2006-02-16 Sumitomo Chemical Co Ltd コモンマーモセット由来のヒポキサンチングアニンホスホリボシルトランスフェラーゼ遺伝子及びその利用
EA012799B1 (ru) 2004-08-16 2009-12-30 Кварк Фармасьютикалс, Инк. Терапевтические применения ингибиторов rtp801
EP2527837A1 (en) 2004-10-04 2012-11-28 University of Washington Methods of inhibiting cell death or inflammation in a mammal
DE102004059781A1 (de) * 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Verwendung der Serum-/Glucocorticoid regulierten Kinase
WO2006069000A2 (en) * 2004-12-21 2006-06-29 The Brigham And Women's Hospital, Inc. Klf2 as a mediator of statin activity
US7795503B2 (en) 2005-02-22 2010-09-14 Ceres, Inc. Modulating plant alkaloids
EP2343320B1 (en) 2005-03-25 2017-10-25 GITR, Inc. Anti-gitr antibodies and uses thereof
US8124839B2 (en) 2005-06-08 2012-02-28 Ceres, Inc. Identification of terpenoid-biosynthesis related regulatory protein-regulatory region associations
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
WO2008054534A2 (en) * 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
WO2007141796A2 (en) * 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
US8343918B2 (en) 2006-06-09 2013-01-01 Novartis Ag Stabilized insulin-like growth factor polypeptides
EP2084296B1 (en) * 2006-09-29 2015-08-05 Agendia N.V. High-throughput diagnostic testing using arrays
WO2008065637A1 (en) * 2006-12-01 2008-06-05 University College York - National University Of Ireland, Cork Treatment of disease
US7705122B2 (en) * 2006-12-04 2010-04-27 Intrexon Corporation mTOR ligands and polynucleotides encoding mTOR ligands
MX2009006438A (es) * 2006-12-19 2009-08-07 Sanofi Aventis Genes de exon unico que codifican nuevos peptidos bioactivos.
US7872119B2 (en) 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
ES2424976T3 (es) * 2007-06-03 2013-10-10 Oncotx, Inc. Isoformas relativas al cáncer de componentes de complejos de factores de transcripción como biomarcadores y dianas de fármacos
ES2591281T3 (es) * 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
DE102007041657A1 (de) * 2007-09-03 2009-03-05 Protagen Ag Markersequenzen für Multiple Sklerose und deren Verwendung
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
KR100983475B1 (ko) * 2008-01-17 2010-09-24 고려대학교 산학협력단 당뇨병성 망막증 진단용 바이오마커
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010051502A2 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
EP2362877A4 (en) * 2008-11-06 2012-05-09 Univ Columbia POLYNUCLEOTIDES CODING FOR HUMAN TRIM-CYP FUSION POLYPEPTIDE, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF
EP2373690B1 (en) 2008-12-08 2015-02-11 Compugen Ltd. Antibodies specific for tmem154
PT2406284T (pt) 2009-03-10 2016-09-29 Biogen Ma Inc Anticorpos anti-bcma
WO2010141999A1 (en) * 2009-06-12 2010-12-16 The University Of Queensland Agents and methods for diagnosing and treating ankylosing spondylitis
AU2011248490B2 (en) * 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
CN103096912A (zh) * 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2012031099A2 (en) 2010-09-02 2012-03-08 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
US10273294B2 (en) 2010-10-11 2019-04-30 University Of Southern California Compositions and methods for treating HIF-1α over-expressing cancers
WO2012051207A2 (en) * 2010-10-11 2012-04-19 University Of Southern California FRAGMENT OF SECRETED HEAT SHOCK PROTEIN-90ALPHA (Hsup90ALPHA) AS VACCINES OR EPITOPE FOR MONOCLONAL ANTIBODY DRUGS OR TARGET FOR SMALL MOLECULE DRUGS AGAINST A RANGE OF SOLID HUMAN TUMORS
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CA2841111A1 (en) 2011-07-08 2013-01-17 Novartis Ag Novel pyrrolo pyrimidine derivatives
US9522943B2 (en) 2012-03-02 2016-12-20 Rhode Island Hospital, A Lifespan-Partner Treating human immunodeficiency virus infections
EP2820045B1 (en) 2012-03-02 2018-08-22 Vaccinex, Inc. Methods for the treatment of b cell-mediated inflammatory diseases
AU2013234046B2 (en) * 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014093417A1 (en) * 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
CN105408355A (zh) 2013-01-31 2016-03-16 瓦克纳斯有限公司 用于提高免疫球蛋白a水平的方法
JP6205175B2 (ja) * 2013-05-16 2017-10-04 株式会社Resvo 精神・神経疾患バイオマーカー
HUE044730T2 (hu) 2013-09-20 2019-11-28 Bristol Myers Squibb Co Anti-LAG-3 antitestek és Anti-PD-1 antitestek kombinációja tumorok kezelésére
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US20160310567A1 (en) * 2015-04-23 2016-10-27 Florida Atlantic University Compositions for inhibiting viral replication and methods of use and production thereof
CN107743586B (zh) 2015-06-03 2021-07-02 百时美施贵宝公司 用于癌症诊断的抗gitr抗体
US11391744B2 (en) 2015-06-08 2022-07-19 Arquer Diagnostic Limited Methods and kits
ES2806498T3 (es) 2015-06-08 2021-02-17 Arquer Diagnostics Ltd Métodos para el análisis de una muestra de orina
CA3005855A1 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US11400142B2 (en) * 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
EP3395354B1 (en) * 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
EP3556384B1 (en) 2016-12-15 2024-04-10 Talengen International Limited Plasminogen for use in treating diabetes
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
US11623945B2 (en) 2017-02-06 2023-04-11 The United States Of America, As Represented By The Secretary Of Agriculture Immunostimulating compositions and uses therefore
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
BR112019020610A2 (pt) 2017-05-30 2020-04-22 Bristol-Myers Squibb Company tratamento de tumores positivos para o lag-3
WO2019153029A1 (en) * 2018-02-06 2019-08-15 Meat & Livestock Australia Limited Polypeptide, compositions and uses thereof

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
WO1989005859A1 (en) 1987-12-21 1989-06-29 The Upjohn Company Agrobacterium mediated transformation of germinating plant seeds
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
DE394538T1 (de) 1989-04-28 1991-04-11 Rhein Biotech Ges. Fuer Biotechnologische Prozesse Und Produkte Mbh, 4000 Duesseldorf, De Hefezellen der schwanniomyces-gattung.
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
WO1993005169A1 (en) * 1991-08-30 1993-03-18 Fred Hutchinson Cancer Research Center Hybrid cytokines
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
PT616812E (pt) 1993-03-24 2000-04-28 Berlex Biosciences Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
US6562333B1 (en) * 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6326469B1 (en) * 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869286A (en) * 1995-03-23 1999-02-09 Immunex Corporation Receptor that binds IL-17
AU2582897A (en) 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US6479254B2 (en) * 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
US5861308A (en) * 1996-08-21 1999-01-19 Ludwig Institute For Cancer Research Isolated nucleic acids associated with T cell activation and uses thereof
JP2002511732A (ja) * 1996-10-11 2002-04-16 ザ・テキサス・エイ・アンド・エム・ユニヴァーシティ・システム トランスジェニック動物を発生させるための組成物および方法
US6183951B1 (en) * 1997-04-11 2001-02-06 Prometheus Laboratories, Inc. Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy
AU764441B2 (en) * 1998-02-09 2003-08-21 Genset S.A. cDNAs encoding secreted proteins
EP1220905A2 (en) * 1999-03-08 2002-07-10 Genentech Inc. Composition and methods for the treatment of immune related diseases
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2000064479A1 (en) * 1999-04-27 2000-11-02 Antibody Systems, Inc. Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
JP2002191363A (ja) * 1999-07-29 2002-07-09 Herikkusu Kenkyusho:Kk 全長cDNA合成用プライマー、およびその用途
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
HUP0303656A3 (en) * 2000-10-23 2006-03-28 Bristol Myers Squibb Co Modulators of bruton's tyrosine kinase, their identification and use
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
WO2002064739A2 (en) * 2001-02-09 2002-08-22 Johns Hopkins University A cytokine related structurally to il-17
GB0105402D0 (en) * 2001-03-05 2001-04-18 Inpharmatica Ltd Novel proteins
US20040101874A1 (en) * 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome

Similar Documents

Publication Publication Date Title
JP2010115195A5 (ja)
JP2010207229A5 (ja)
JP2012115275A5 (ja)
JP2011050389A5 (ja)
JP2011512817A5 (ja)
JP2013516633A5 (ja)
JP2010220614A5 (ja)
JP2012509295A5 (ja)
JP2006516094A5 (ja)
JP2010521655A5 (ja)
RU2009135270A (ru) Способы выявления воспалительного заболевания кишечника
SI2524060T1 (en) Investigation for JC virus antibodies
RU2009126617A (ru) Собачий тимусный стромальный лимфопоэтический белок и его применение
EP3455371A1 (en) Tissue-specific exosomes as biomarkers
JP2013539032A5 (ja)
Bilić et al. Serum proteome profiling in canine idiopathic dilated cardiomyopathy using TMT-based quantitative proteomics approach
NZ598035A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
RU2019103403A (ru) Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью
Bourgonje et al. Phage-display immunoprecipitation sequencing of the antibody epitope repertoire in inflammatory bowel disease reveals distinct antibody signatures
JP2011518338A5 (ja)
JP2014524583A5 (ja)
CN111596070B (zh) 一种三疣梭子蟹原肌球蛋白过敏检测试剂的应用
JP2014501929A5 (ja)
JP2011513759A5 (ja)
JP2007525213A5 (ja)